Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 22 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Ketorolac Tromethamine Tablets. The tablets are intended to relieve moderately severe pain, typically following surgery, and will be manufactured in Ahmedabad, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases